About Us
MISSION
CORSA Inc. is a Minneapolis-based Company that has developed patented Convective Water Vapor Energy (C-WAVE) to dramatically improve the ease, efficiency, and efficacy of treating Barrett’s Esophagus, reducing the risk of esophageal cancer for millions of patients around the world.
FOUNDER, MICHAEL HOEY
“I am thrilled to bring CORSA’s patented Endoscopic VAPOR Therapy to the Gastroenterology community. I have introduced VAPOR to several other healthcare specialties and have helped manage successful medical device VAPOR startups like NxThera and Francis Medical, where it has delivered proven, predictable results, unlike any other energy source. Since testing VAPOR in various GI applications, we're confident it will also bring significant benefits in this space.”
Michael Hoey, Founder
THE PROBLEM: Barrett’s Esophagus
Barrett’s Esophagus is a condition in which the cells lining the esophagus begin to change due to chronic exposure to stomach acid and bile. Barrett’s Esophagus is the primary risk factor for developing esophageal cancer, one of the fastest-growing cancers in the world.
CORSA is dedicated to developing a solution that not only treats Barrett’s Esophagus but also significantly reduces the risk of progression to esophageal cancer.
OUR APPROACH: Convective Water Vapor Energy
Convective Water Vapor Energy (C-WAVE) Therapy uses the energy created in a few drops of heated water to ablate tissue in the GI Tract. C-WAVE is designed for the ablation of Barrett’s Esophagus.
